Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      NDO D 2
      NDO M 2

      UK-BUO-250027. DOP: May 2025.

      Administering BOTOX® for your patients with neurogenic detrusor overactivity (NDO)

      BOTOX® provides approximately 9 months of symptom relief†5

      X1470 NDO UK BOTOX Sales Aid - New Branding_17 1

      Image adapted from BOTOX® Summary of Product Characteristics5

      †As demonstrated by patients who continued into the open label extension study.

      BOTOX® in NDO: Treatment benefit sustained over time6

      Reductions in mean UI episodes per day at Week 6 after BOTOX® 200U compared with baseline were consistent during the 4 years of treatment (n=122; primary endpoint)6

      X1470 NDO UK BOTOX Sales Aid - New Branding_13 1

      Adapted from Rovner, 2016.6

      Study context: Post-hoc analysis of 227 patients with urinary incontinence due to NDO, who completed 4 years of treatment following an initial 52-week phase 3 trial and then a 3-year open label extension study. Primary efficacy endpoint was change from baseline in UI episodes per day at Week 6.6

      BOTOX® duration of effect6

      X1470 NDO UK BOTOX Sales Aid - New Branding_12 2

      Adapted from Rovner, 2016.6

      Study context: Post-hoc analysis of 227 patients with urinary incontinence due to NDO, who completed 4 years of treatment following an initial 52-week phase 3 trial and then a 3-year open label extension study. Primary efficacy mendpoint was change from baseline in UI episodes per day at Week 6. Overall median duration of effect by time in 112 patients on 200U based on 4-week months. Time to request for re-treatment was calculated from date of patient request for re-treatment in relation to previous treatment date.6

      I-QoL: Incontinence-quality of life; NDO: neurogenic detrusor overactivity; SmPC: summary of product characteristics; UI: urinary incontinence.

      Request further information on BOTOX®

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Rovner E, Kohan A et al. Long-term efficacy and safety of Onabotulinum toxin A in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J Urol. 2016;196(3)801-808

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Rovner E, Kohan A et al. Long-term efficacy and safety of Onabotulinum toxin A in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J Urol. 2016;196(3)801-808

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: June 2025. UK-BUO-250048.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250217. Date of preparation June 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.